US 11525001
Anti-CD8 antibodies and uses thereof
granted A61KA61K2039/505A61K45/06
Quick answer
US patent 11525001 (Anti-CD8 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 56
- CPC classes
- A61K, A61K2039/505, A61K45/06, A61K49/0032, A61K49/0058